Bridge to Recovery: What Remains to be Discovered?

Cardiology Clinics

Volumn 29, Issue 4, 2011, Pages 531-547

  Ibrahim, Michael ^a   Terracciano, Cesare M ^a   Yacoub, Magdi H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Cardiac recovery; Harefield protocol; LVAD; Mechanical unloading

Indexed keywords

BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL L TYPE; CALCIUM ION; CLENBUTEROL; COLLAGEN; DOBUTAMINE; SOMATOMEDIN C; TOLL LIKE RECEPTOR 4;

ADRENERGIC SYSTEM; APOPTOSIS; CELL REGENERATION; CONGESTIVE CARDIOMYOPATHY; DISEASE SEVERITY; EXCITATION CONTRACTION COUPLING; EXTRACELLULAR MATRIX; FUNCTIONAL STATUS; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART TRANSPLANTATION; HUMAN; INNATE IMMUNITY; ISCHEMIC CARDIOMYOPATHY; LEFT VENTRICULAR ASSIST DEVICE; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RESOURCE ALLOCATION; REVIEW;

APOPTOSIS; COMBINED MODALITY THERAPY; CYTOSKELETAL PROTEINS; DEVICE REMOVAL; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; EXTRACELLULAR MATRIX; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; IMMUNITY, INNATE; MEMBRANE PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PATIENT SELECTION; POSTOPERATIVE CARE; PROSTHESIS DESIGN; PROSTHESIS IMPLANTATION; RECEPTORS, ADRENERGIC, BETA; RECOVERY OF FUNCTION; TIME FACTORS;

EID: 80655128370     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2011.08.007     Document Type: Review

References (96)

1. World Health Organisation Global Infobase 2011, World Health Organisation.
2. Frazier O.H., Benedict C.R., Radovancevic B., et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg 1996, 62:675-681.
3. Frazier O.H. First use of an untethered, vented electric left ventricular assist device for long-term support. Circulation 1994, 89:2908-2914.
4. Mann D.L., Willerson J.T. Left ventricular assist devices and the failing heart: a bridge to recovery, a permanent assist device, or a bridge too far?. Circulation 1998, 98:2367-2369.
5. Maybaum S., Mancini D., Xydas S., et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007, 115:2497-2505.
6. Mancini D.M., Beniaminovitz A., Levin H., et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998, 98:2383-2389.
7. Yacoub M.H. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 2001, 22:534-540.
8. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355:1873-1884.
9. Yacoub M.H., Terracciano C.M. The Holy Grail of LVAD-induced reversal of severe chronic heart failure: the need for integration. Eur Heart J 2011, 32:1052-1054.
10. Fatkin D., Otway R., Richmond Z. Genetics of dilated cardiomyopathy. Heart Fail Clin 2010, 6:129-140.
11. Yusuf S.W., Ilias-Khan N.A., Durand J.B. Chemotherapy-induced cardiomyopathy. Expert Rev Cardiovasc Ther 2011, 9:231-243.
12. Abboud J., Murad Y., Chen-Scarabelli C., et al. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 2007, 118:295-303.
13. Unosawa S., Hata M., Sezai A., et al. Successful recovery using surgical intervention to treat ischemic cardiomyopathy and cardiogenic shock. Ann Thorac Cardiovasc Surg 2010, 16:52-54.
14. Beurtheret S., Mordant P., Pavie A., et al. Successful weaning of a left ventricular assist device implanted for ischemic heart failure. Interact Cardiovasc Thorac Surg 2010, 11:507-509.
15. Miller L.W. Left ventricular assist devices are underutilized. Circulation 2011, 123:1552-1558.
16. Stewart G.C., Stevenson L.W. Keeping left ventricular assist device acceleration on track. Circulation 2011, 123:1559-1568.
17. Stevenson L.W., Pagani F.D., Young J.B., et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009, 28:535-541.
18. Terracciano C.M., Miller L.W., Yacoub M.H. Contemporary use of ventricular assist devices. Annu Rev Med 2010, 61:255-270.
19. Birks E.J., George R.S., Hedger M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011, 123(4):381-390.
20. Oriyanhan W., Tsuneyoshi H., Nishina T., et al. Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. J Heart Lung Transplant 2007, 26:16-23.
21. Dalby M.C., Banner N.R., Tansley P., et al. Left ventricular function during support with an asynchronous pulsatile left ventricular assist device. J Heart Lung Transplant 2003, 22:292-300.
22. George R.S., Yacoub M.H., Tasca G., et al. Hemodynamic and echocardiographic responses to acute interruption of left ventricular assist device support: relevance to assessment of myocardial recovery. J Heart Lung Transplant 2007, 26:967-973.
23. Kinoshita M., Takano H., Taenaka Y., et al. Cardiac disuse atrophy during LVAD pumping. ASAIO Trans 1988, 34:208-212.
24. Soppa G.K., Lee J., Stagg M.A., et al. Prolonged mechanical unloading reduces myofilament sensitivity to calcium and sarcoplasmic reticulum calcium uptake leading to contractile dysfunction. J Heart Lung Transplant 2008, 27:882-889.
25. Ibrahim M., Al Masri A., Navaratnarajah M., et al. Prolonged mechanical unloading affects cardiomyocyte excitation-contraction coupling, transverse-tubule structure, and the cell surface. FASEB J 2010, 24:3321-3329.
26. Soppa G.K., Smolenski R.T., Latif N., et al. Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am J Physiol Heart Circ Physiol 2005, 288:H1468-H1476.
27. Siedlecka U., Arora M., Kolettis T., et al. Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2008, 295:H1917-H1926.
28. Barton P.J., Bhavsar P.K., Felkin L.E., et al. Morphological and molecular effects of clenbuterol on cardiac myocytes - role of IGF-1. J Heart Lung Transplant 2004, 23. [abstract], S53.
29. Frazier O.H., Myers T.J. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg 1999, 68:734-741.
30. Dandel M., Weng Y., Siniawski H., et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation 2008, 118:S94-105.
31. Hetzer R., Muller J.H., Weng Y.G., et al. Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy. J Thorac Cardiovasc Surg 2000, 120:843-853.
32. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
33. Dipla K., Mattiello J.A., Jeevanandam V., et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998, 97:2316-2322.
34. Terracciano C.M., Hardy J., Birks E.J., et al. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 2004, 109:2263-2265.
35. Zafeiridis A., Jeevanandam V., Houser S.R., et al. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998, 98:656-662.
36. Madigan J.D., Barbone A., Choudhri A.F., et al. Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device. J Thorac Cardiovasc Surg 2001, 121:902-908.
37. Bers D.M. Altered cardiac myocyte Ca regulation in heart failure. Physiology (Bethesda) 2006, 21:380-387.
38. Crossman D.J., Ruygrok P.R., Soeller C., et al. Changes in the organization of excitation-contraction coupling structures in failing human heart. PLoS One 2011, 6. e17901.
39. Ibrahim M., Navaratnarajah M., Siedlecka U., et al. Mechanical unloading of failing hearts normalises calcium-induced calcium release by reverse remodelling of the T-Tubule system. Circulation 2010, 122. [abstract], A17308.
40. Birks E.J., Felkin L.E., Banner N.R., et al. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 2004, 23:228-235.
41. Birks E.J., Latif N., Owen V., et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001, 104:I233-I240.
42. Yamagishi T., Oshima K., Mohara J., et al. Cytokine induction owing to LVAD support in canine models. Transplant Proc 1999, 31:1992-1993.
43. Drakos S.G., Terrovitis J.V., Nanas J.N., et al. Reverse electrophysiologic remodeling after cardiac mechanical unloading for end-stage nonischemic cardiomyopathy. Ann Thorac Surg 2011, 91:764-769.
44. Harding J.D., Piacentino V., Gaughan J.P., et al. Electrophysiological alterations after mechanical circulatory support in patients with advanced cardiac failure. Circulation 2001, 104:1241-1247.
45. Ibrahim M, Gorelik J, Yacoub M, et al. The structure and function of cardiac T-Tubules in health and disease. Proceedings of the Royal Society, Series B 2011. Proc Biol Sci 2011;278(1719):2714-23.
46. Margulies K.B., Matiwala S., Cornejo C., et al. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res 2005, 96:592-599.
47. Vatta M., Stetson S.J., Perez-Verdia A., et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 2002, 359:936-941.
48. Latif N., Yacoub M.H., George R., et al. Changes in sarcomeric and non-sarcomeric cytoskeletal proteins and focal adhesion molecules during clinical myocardial recovery after left ventricular assist device support. J Heart Lung Transplant 2007, 26:230-235.
49. Hall J.L., Birks E.J., Grindle S., et al. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur Heart J 2007, 28:613-627.
50. de Jonge N., van Wichen D.F., Schipper M.E., et al. Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol 2002, 39:963-969.
51. Kanchanawong P., Shtengel G., Pasapera A.M., et al. Nanoscale architecture of integrin-based cell adhesions. Nature 2010, 468:580-584.
52. Nikolaev V.O., Moshkov A., Lyon A.R., et al. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 2010, 327:1653-1657.
53. Ogletree-Hughes M.L., Stull L.B., Sweet W.E., et al. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation 2001, 104:881-886.
54. Bick R.J., Grigore A.M., Poindexter B.J., et al. Left ventricular unloading with an assist device results in receptor relocalization as well as increased beta-adrenergic receptor numbers: are these changes indications for outcome?. J Card Surg 2005, 20:332-336.
55. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
56. Mital S., Loke K.E., Addonizio L.J., et al. Left ventricular assist device implantation augments nitric oxide dependent control of mitochondrial respiration in failing human hearts. J Am Coll Cardiol 2000, 36:1897-1902.
57. Bartling B., Milting H., Schumann H., et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation 1999, 100:II216-II223.
58. Milting H., Bartling B., Schumann H., et al. Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy-first results of the Halle Assist Induced Recovery Study (HAIR). Thorac Cardiovasc Surg 1999, 47:48-50.
59. Francis G.S., Anwar F., Bank A.J., et al. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail 1999, 5:308-315.
60. Baba H.A., Grabellus F., August C., et al. Reversal of metallothionein expression is different throughout the human myocardium after prolonged left-ventricular mechanical support. J Heart Lung Transplant 2000, 19:668-674.
61. Beltrami A.P., Urbanek K., Kajstura J., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001, 344:1750-1757.
62. Engel F.B., Hsieh P.C., Lee R.T., et al. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci U S A 2006, 103:15546-15551.
63. Hosoda T., Kajstura J., Leri A., et al. Mechanisms of myocardial regeneration. Circ J 2010, 74:13-17.
64. Leri A., Kajstura J., Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005, 85:1373-1416.
65. Urbanek K., Torella D., Sheikh F., et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A 2005, 102:8692-8697.
66. Klotz S., Burkhoff D., Garrelds I.M., et al. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?. Eur Heart J 2009, 30:805-812.
67. Thompson L.O., Skrabal C.A., Loebe M., et al. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res 2005, 123:25-32.
68. Adler C.P., Sandritter W. Alterations of substances (DNA, myoglobin, myosin, protein) in experimentally induced cardiac hypertrophy and under the influence of drugs (isoproterenol, cytostatics, strophanthin). Basic Res Cardiol 1980, 75:126-138.
69. Sandritter W., Adler C.P. Polyploidization of heart muscle nuclei as a prerequisite for heart growth and numerical hyperplasia in heart hypertrophy. Recent Adv Stud Cardiac Struct Metab 1976, 12:115-127.
70. Wohlschlaeger J., Levkau B., Brockhoff G., et al. Hemodynamic support by left ventricular assist devices reduces cardiomyocyte DNA content in the failing human heart. Circulation 2010, 121:989-996.
71. Barton P.J., Felkin L.E., Birks E.J., et al. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation 2005, 112:I46-I50.
72. Duerr R.L., Huang S., Miraliakbar H.R., et al. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995, 95:619-627.
73. Duerr R.L., McKirnan M.D., Gim R.D., et al. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 1996, 93:2188-2196.
74. Li Q., Li B., Wang X., et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997, 100:1991-1999.
75. Musaro A. Growth factor enhancement of muscle regeneration: a central role of IGF-1. Arch Ital Biol 2005, 143:243-248.
76. Pelosi L., Giacinti C., Nardis C., et al. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J 2007, 21:1393-1402.
77. Santini M.P., Tsao L., Monassier L., et al. Enhancing repair of the mammalian heart. Circ Res 2007, 100:1732-1740.
78. Welch S., Plank D., Witt S., et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002, 90:641-648.
79. Milting H., Scholz C., Arusoglu L., et al. Selective upregulation of beta1-adrenergic receptors and dephosphorylation of troponin I in end-stage heart failure patients supported by ventricular assist devices. J Mol Cell Cardiol 2006, 41:441-450.
80. Matkovich S.J., Van Booven D.J., Youker K.A., et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009, 119:1263-1271.
81. Klotz S., Foronjy R.F., Dickstein M.L., et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005, 112:364-374.
82. Li Y.Y., Feng Y., McTiernan C.F., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001, 104:1147-1152.
83. Matsumiya G., Monta O., Fukushima N., et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy?. J Thorac Cardiovasc Surg 2005, 130:699-704.
84. Saito S., Matsumiya G., Sakaguchi T., et al. Cardiac fibrosis and cellular hypertrophy decrease the degree of reverse remodeling and improvement in cardiac function during left ventricular assist. J Heart Lung Transplant 2010, 29:672-679.
85. Drakos S.G., Kfoury A.G., Hammond E.H., et al. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol 2010, 56:382-391.
86. Akgul A., Skrabal C.A., Thompson L.O., et al. Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transplant 2004, 23:709-715.
87. Bruckner B.A., Stetson S.J., Perez-Verdia A., et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 2001, 20:457-464.
88. Thohan V., Stetson S.J., Nagueh S.F., et al. Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. J Heart Lung Transplant 2005, 24:566-575.
89. Bruggink A.H., van Oosterhout M.F., De J.N., et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006, 25:1091-1098.
90. Felkin L.E., Lara-Pezzi E., George R., et al. Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transplant 2009, 28:117-122.
91. Arnold J.M., Yusuf S., Young J., et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003, 107:1284-1290.
92. Klotz S., Danser A.H., Foronjy R.F., et al. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol 2007, 49:1166-1174.
93. MacKenna D., Summerour S.R., Villarreal F.J. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 2000, 46:257-263.
94. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005, 65:40-51.
95. Smith R.S., Smith T.J., Blieden T.M., et al. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997, 151:317-322.
96. Egerstedt M. Complex networks: degrees of control. Nature 2011, 473:158-159.